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INTRODUCTION 
 Pulmonary hypertension is characterized by increased pulmonary 
arterial pressure and secondary right ventricular failure. It is progressive, if 
untreated it turns fatal and rate of progression is high among renal failure 
patients. The prevalence of chronic kidney disease in developed world is 
13%
1
.Both the complication worsens one another, if they co-exist. 
Classification of PH has gone through various changes and in 1998 
PAH group have concluded with Group 1, 2, 3, 4, and 5, which was 
approved by WHO
2
. 
According to WHO classification pulmonary artery hypertension has 
5 categories. Usually it is done by right heart catheterization and the non 
invasive method is Doppler echocardiography study. The echocardiography 
parameters taken into account are right ventricular size, thickness and 
function, valve anatomy and functions.  
The maximum tricuspid regurgitant jet velocity is recorded and the 
pulmonary artery systolic pressure (PASP) is then calculated: 
PASP = (4 x TRV squared) + RAP  
  TRV is the maximum tricuspid regurgitant jet velocity and RAP is the 
right atrial pressure estimated from the size and respiratory variation of flow 
in the inferior vena cava.  
Doppler echocardiography of limited value when an adequate 
tricuspid regurgitant jet cannot be sampled.
3
  
Patients with PHT may have echocardiography signs of right 
ventricular pressure overload, including paradoxical bulging of the septum 
into the left ventricle during systole and hypertrophy of the right ventricular 
free wall and trabeculae.  
As the right ventricle fails, there is dilation and hypokinesis, septal 
flattening, right atrial dilation, and tricuspid regurgitation. The tricuspid 
regurgitation, a secondary manifestation of dilation of the tricuspid annulus 
and right ventricle and not due to intrinsic valve abnormality
4
. Other 
findings associated with pulmonary hypertension are pulmonic insufficiency 
and mid systolic closure of the pulmonic valve
5
.  
The echocardiography findings of PHT are summarized in the figure.  
Based upon a Doppler echocardiography study
7
, it can be determined 
if PHT is likely, unlikely, or possible
6
:  
1. PHT is likely if the PASP is >50 and the TRV is >3.4  
2. PHT is unlikely if the PASP is ≤36, the TRV is ≤2.8, and there are no 
other suggestive findings.  
  PHT is possible with other combinations of findings  
One of limitation of Doppler echocardiography is that it may be 
misleading, when patient’s inadequate tricuspid regurgitation jet is over-
interpreted. 
WHO Diagnostic Classification of Pulmonary Hypertension
7 
Class Definition Conditions 
I Idiopathic, familial, and 
associated PAH 
Connective tissue diseases, HIV infection, congenital 
heart disease, portal hypertension and pulmonary veno-
occlusive disease, drugs and toxins. 
II PH associated with left-
sided heart disease 
Left-sided heart systolic dysfunction, left-sided heart 
diastolic dysfunction, left-sided valvular disease (mitral 
and/or aortic) 
III PH associated with lung 
diseases and/or hypoxia 
COPD, interstitial lung disease, sleep apnea 
IV Chronic thromboembolic 
PH 
Obstruction of pulmonary arterial vessels (proximal or 
distal) by thromboemboli, tumors, or foreign bodies 
V PH with unclear or 
multifactorial causes 
Dialysis-dependent CKD; several hematologic, 
systemic, and metabolic disorders; miscellaneous 
Note: Class I PH formerly was referred to as pre capillary PH; class II, as 
post capillary PH. 
PH in CKD patients on maintenence haemodialysis is likely to have 
worse prognosis, and unless found earlier and worked up for Renal 
transplant and undergone renal transplant at the earliest, it can’t be reverted. 
Therefore, in this study effect of renal transplant on PH and its outcome is 
done by Doppler echocardiography in pre transplant and post transplant 
period during 3
rd
 and 6
th
 month. 
AIM AND OBJECTIVES 
To find the status of pulmonary hypertension present in the pre 
transplant period after 3
rd
 and 6
th
 month of renal transplantation using 
Doppler echocardiography   
REVIEW OF LITERATURE 
 Chronic kidney disease (CKD) is a heterogeneous group of disorders 
resulting in number of changes both structural and functional abnormalities, 
or both persisting for minimum of 3months or more. Abnormality in urine 
with proteinuria or hematuria and structure or histological features, with or 
without fall in GFR <60mL/min/1.7m2. CKD is divided into five stages 
according GFR and Albuminuria by KDIGO 2012
9
. 
 
 
GFR stage 3 CKD (a GFR of 30 to 59mL /min per 1.73 m
2
) has been 
subdivided into GFR stages 3a and 3b to more accurately; patients on 
dialysis are sub classified as GFR stage 5D. 
  Albuminuria — The three Albuminuria stages follow as "normal", 
"high","very high" this grading is considered because of its high predictive 
of mortality. With consideration of relative risk and general outcome GFR 
and ACR stages was established. Based upon these findings, a "heat map" 
can be constructed that divides patients with CKD
10
. 
Moderate risk (yellow) — 73 percent of patients with CKD 
High risk (orange) — 18 percent of patients with CKD 
Very high risk (red) — 9 percent of patients with CKD 
Both Albuminuria and GRF goes hand on hand both can be used 
together for a patient progress on CKD. Evaluation of GFR serum creatinine 
and a GFR estimation equation is required, other additional test which are 
used is used cystatin C or a clearance method. But it should be done in 
properly calibrated lab and also a clinical assessment, regardless of age, sex, 
and degree of proteinuria or Albuminuria. The estimation of eGFR is 
required to improve the management of common disease in the population
11
. 
METHODS OF ESTIMATION GFR:
(8,9,10,11) 
1. Cockcroft-Gault equation — The Cockcroft-Gault equation allows the 
creatinine clearance to be estimated from the serum creatinine in a 
patient with a stable serum creatinine. 
2. MDRD study equations — several equations were derived from data 
on adult patients enrolled in the MDRD with six-variable equation 
initially and then with four variables. GFR measured at baseline using 
urinary clearance of iothalamate. 
3. CKD-EPI is a gold standard and superior when GFR is normal or 
mildly reduced — The CKD-EPI equation was developed with the 
data pooled from 10 studies to provide a more accurate estimate of 
GFR among individuals with normal or only mildly reduced GFR (ie, 
above 60 mL/min per 1.73 m
2
) 
 NATURAL HISTORY OF RENAL DISEASE: 
The initial injury to the kidney results in various forms ranging from 
asymptomatic hemauria to CKD on MHD. Poststreptococcal 
glomerulonephritis in children or lupus in some patient with repeated insult 
to kidneys lead to permanent damage. 
Kidney has a special ability of „Adaptive Hyperfiltration‟ process 
which patient can have mild renal failure or near normal creatinine. 
Additional homeostasis mechanism helps total body water, sodium 
potassium, calcium and phosphorus remains normal
12
. 
ESRD INCIDENCE AND PREVALENCE: 
Lack of proper maintenance of registry, makes an inaccurate 
estimation, so estimation is made from RRT in hospitals. Many patients are 
not aware of the disease, with no medical attestation, estimates has shown 
55,000 patients on RRT. Dialysis population will annually about 10-20%. 
Gender in CKD: Women generally have 10-15% les Nephron number
13
. 
The rate of difference in the incidence and prevalence is by glomerular mass, 
response to hormones, cytokines and other circulating factors also with 
aging and reduction in Nephron number.  
 
Complication of CKD:  
1. Reversible causes of renal failure:  
a. Decreased renal perfusion 
b. Administration of nephrotoxic drugs 
c. Urinary tract obstruction 
2. Slowing the rate of progression 
a. Principal targets for renal protection 
b. Other targets for renal protection 
3. Treatment of the complications of renal failure  
a. Volume overload 
b.  Hyperkalemia 
c. Metabolic acidosis 
d. Mineral and bone disorders (MBD) 
e. Hypertension 
f. Anaemia 
g. Dyslipidemia 
h. Sexual dysfunction 
4. Treatment of complications of ESRD 
a. Malnutrition 
b. Uremic bleeding 
c. Pericarditis 
d. Uremic neuropathy 
e. Thyroid dysfunction 
5. Cardiovascular risk factor  
 
CARDIOVASCULAR RISK IN CKD ON MHD: 
Traditional risk: Smoking, Hypertension, Diabetes, Dyslipidemia, Old Age 
are highly prevalent in CKD group. 
Non traditional risk factors: Uraemia, Anaemia, Elevated Cytokines, 
Increased Calcium Intake, Abnormality in Bone Metabolism, Nutritional 
Status. 
PULMONARY HYPERTENSION IN CKD: 
Introduction: 
PH has gone through a series of change since the first version was 
proposed in 1973 at the first international conference on primary pulmonary 
hypertension endorsed by the World Health Organization. Till fourth World 
Symposium on PH held in 2008 in Dana Point, California, and approved by 
WHO. During the last 2 decades mild to moderate forms of PH has become 
more common. Pulmonary hypertension in chronic kidney disease patient is 
not associated with connective tissue disorder or a systemic disease; 
decrease in renal function can be a trigger for the development of pulmonary 
hypertension in CKD population. 
A clinical history and clinical manifestation and etiology will be 
reliable on PH. Pressure overload on RV (right ventricle) leads to increase in 
dilatation and hypertrophy of RV. This may progress and lead to TR 
tricuspid regurgitation and atrial dilatation. Pulmonary hypertension initially 
can be managed medically, but with CKD stage V on haemodialysis renal 
transplant will be a better option. 
EPIDEMIOLOGY: 
A large survey documented in US that pulmonary hypertension during 
two decades 1980-2002 had death rate ranges from( 5.2-5.4/100,000).  
The prevalence of group 1 PAH in the general population is estimated 
to be 5 to 15 cases per one million adults
15
.  
Definitions: 
 For the Diagnosis and Treatment of Pulmonary Hypertension in year 
2008 a team of group worked that are the European Society of Cardiology 
(ESC), the European Respiratory Society (ERS) and International Society of 
Heart and Lung Transplantation (ISHLT). 
Accordingly Pulmonary hypertension (PH) is a hemodynamic and 
path physiological condition defined as an increase in mean pulmonary 
arterial pressure (PAP) -25 mmHg at rest as assessed by right heart 
catheterization. 
 
 NOMENCLATURE: 
1. Pulmonary arterial hypertension (PAH) refers to group 1 PAH.  
2. Pulmonary hypertension (PH) refers to any of group 2 PH through              
group 5 PH.  
a. The definition of PH on exercise as a mean PAP 30 mmHg as 
assessed by right heart catheterization is not supported by 
published data. 
b. Pulmonary arterial hypertension (PAH, group 1) is a clinical 
condition characterized by the presence of pre-capillary PH in the 
absence of other causes of pre-capillary PH such as PH due to lung 
diseases, chronic thromboembolic PH, or other rare diseases.  
PAH includes different forms that share a similar clinical picture and 
virtually identical pathological changes of the lung microcirculation. 
 
 
 
 
 
 
Haemodynamic definitions of pulmonary hypertension
16 
 
 
 
 
 
 
CLASSIFICATION OF PULMONARY HYPERTENSION:
17 
Group 1 PAH:  Pulmonary arterial hypertension (PAH). 
 These include connective tissue diseases,  
 HIV infection 
 Portal hypertension 
 Congenital heart disease, 
 Schistosomiasis 
 Chronic hemolytic anemia 
 Persistent pulmonary hypertension of the newborn, 
 Pulmonary veno-occlusive disease, 
 Pulmonary capillary hemangiomatosis  
 Drug- and toxin-induced PAH (aminorex, fenfluramine, 
dexfenfluramine, and toxic rapeseed oil)  
 Selective serotonin reuptake inhibitors. 
Group 2 PH: Pulmonary hypertension owing to left heart disease. 
Elevated left atrial and pulmonary venous pressure (pulmonary 
venous hypertension). 
 Systolic dysfunction  
 Diastolic dysfunction   
 Valvular heart disease 
Group 3 PH: Pulmonary hypertension with lung diseases or hypoxemia. 
 Chronic obstructive pulmonary disease 
 Interstitial lung disease, pulmonary diseases with a  
 Mixed restrictive and obstructive pattern 
 Sleep-disordered breathing 
 Alveolar hypoventilation disorders 
 Causes of hypoxemia.  
Group 4 PH: Chronic thromboembolic pulmonary hypertension 
 PH due to thromboembolic occlusion of the proximal or distal 
pulmonary vasculature. 
Group 5 PH: Pulmonary hypertension with unclear multifactorial 
mechanisms.  
 Hematologic disorders (eg, myeloproliferative disorders)  
 Systemic disorders (eg, sarcoidosis)  
 Metabolic disorders (eg, glycogen storage disease) 
 Miscellaneous causes (eg, sickle cell disease, beta-thalassemia). 
WHO CLASSIFICATION:   
WHO diagnostic classification of pulmonary hypertension 
Class Definition Conditions 
I Idiopathic, familial, 
and associated PAH 
Connective tissue diseases, HIV infection, 
congenital heart disease, portal hypertension 
and pulmonary veno-occlusive disease, 
drugs and toxins. 
II PH associated with 
left-sided heart disease 
Left-sided heart systolic dysfunction, left-
sided heart diastolic dysfunction, left-sided 
valvular disease (mitral and/or aortic) 
III PH associated with 
lung diseases and/or 
hypoxia 
COPD, interstitial lung disease, sleep apnea 
IV Chronic 
thromboembolic PH 
Obstruction of pulmonary arterial vessels 
(proximal or distal) by thromboemboli, 
tumors, or foreign bodies 
V PH with unclear or 
multi factorial causes 
Dialysis-dependent CKD; several 
hematologic, systemic, and metabolic 
disorders; miscellaneous 
 
 
 
Who classifies PH in 5 groups. Its  generally measured by mean 
pulmonary artery pressure ≥25 mm Hg at rest, done by right cardiac 
catheterization for group I pulmonary wedge pressure ≤ 15mm Hg . 
Non invasive method also estimates pulmonary hypertension by 
Doppler echocardiography, measurement of PASP (pulmonary artery 
systolic pressure) will be recorded in physiological condition. Studies revels 
that pulmonary hypertension is considered when PASP ≥ 50 mm Hg and or 
TRV is faster than 3.4m/s.  PASP values of 35-29 and TRV values 2.8 – 3.4 
m/s considered most probable when PASP is ≥ 50mmHg.   
 
 
 
 
 
 
 
 
 
PH AND CKD: 
Chronic kidney disease increases the incidence of various diseases, 
commonest one is cardiovascular disease. Mortality is high in this group 
along with CKD G5D.  Chronic kidney disease is associated commonly 
with DM, SHT, and CAD with LV dysfunction, majority having diastolic 
dysfunction. Apart from this chronic kidney disease may also be associated 
with pulmonary hypertension commonly in haemodialysis population.  
The CKD PH is mainly a retrospective study in US population. Right 
sided cardiac catheterization is a definitive modality of investigation for PH 
by international group recommendations. Measurement of PASP in CKD 
G5D is mainly done by Doppler echocardiography which is a non invasive 
method. There is several potential explanations for the development of PH, 
hormonal and metabolic factors which lead to pulmonary arterial 
vasoconstriction and increase pulmonary vascular resistance
 (19, 20, 21)
. 
PROGNOSTIC FACTORS: 
Data from prospective trials suggest that the following factors shows a 
poorer prognosis in patients with PAH
23 
1. Age >45 years  
2. Failure to improve during treatment. 
3. Echocardiography findings. 
4. Decreased pulmonary arterial capacitance  
5. Poor right ventricular contractile reserve  
6. Increased N-terminal pro-brain natriuretic peptide level (NT-pro-BNP 
7. Prolonged QRS duration  
8. Hypocapnia  
9. Co morbid conditions (e.g. , COPD, diabetes)  
PATHOPHYSIOLOGY OF PH: 
The pulmonary vascular endothelium is mono layer, which regulates 
the vascular tone. There will be release of nitric oxide and prostacylin which 
help  in inhibition of platelet aggregation and vasodilator and 
vasoconstriction by Endothelin1 (ET-1) in physiological state. 
Conditions associated with pulmonary hypertension causes reduction 
of prostaglandin and nitric oxide (NO) and increased Thromboxane, 
endothelin  and serotonin which stimulate the endothelial and smooth 
muscle cell proliferation. Apart from this increase in collagen synthesis and 
platelet aggregation also plays a role in PH. 
The main mechanism associated with pulmonary hypertension is 
Endothelial Dysfunction
25
 it is the main trigger which is linked with CKD 
population. High levels of endothelin1 and reduced production of nitric 
oxide (NO) in haemodialysis population predisposes to pulmonary 
hypertension
24
. 
  
Patient on heamodialysis will have overproduction of endogenous  
Asymmetric Dimethylarginine (ADMA) which is the inhibitor of NO. The 
uremic toxins potentially enhances the formation of ADMA in CKD G5D 
population
(26,27)
. Davide et al discussed the pathophysiology of Pulmonary 
Hypertension in CKD population. 
 
METHODOLOGY 
Study method  
  The study was conducted on patients who underwent renal 
transplantation in Department of Nephrology PSGIMSR. Patients with 
pulmonary hypertension pre transplant were taken up for the study after the 
application of inclusion and exclusion criteria and after obtaining consent. 
Demographic, clinical information and laboratory results were 
collected. The assessment of PH was done by Doppler echocardiography pre 
transplant and   3 and 6 months after transplant during follow up.  
Echocardiography  
Echocardiography is performed in all patients during 3&6 month of 
follow up. The major role of echocardiography is to estimate the pulmonary 
artery systolic pressure and to assess right ventricular size, thickness, and 
function.  
Minor roles are to assess right atrial size, left ventricular systolic and 
diastolic function, valve function, pericardial effusions and intra cardiac 
shunts.
 
Echocardiography is performed using sector array probe using   
ultrasonic wave. 
The maximum tricuspid regugatation jet velocity is recorded and the 
pulmonary artery systolic pressure (PASP) is calculated by using the 
formulae 
PASP = (4 x TRV squared) + RAP  
Where, 
TRV- maximum tricuspid regurgitant jet velocity,  
RAP - right atrial pressure which is estimated from the size and respiratory 
variation of flow in the inferior vena cava. 
Doppler echocardiography is limited when an adequate tricuspid 
regurgitant jet cannot be sampled. Echocardiography signs of PHT includes 
right ventricular pressure overload, paradoxical bulging of inter ventricular 
septum into the left ventricle during systole and hypertrophy of the right 
ventricular free wall and trabeculae. As the right ventricle fails, there is 
dilation and hypokinesis, septal flattening, right atrial dilation, and tricuspid 
regurgitation.  
There is no intrinsic abnormality of the tricuspid valve, tricuspid 
regurgitation is a secondary manifestation of dilation and hypokinesis, septal 
flattening, right atrial dilation, dilation of the tricuspid annulus and right 
ventricle
30
.  
Other findings associated with pulmonary hypertension are pulmonic 
insufficiency and midsystolicclosure of the pulmonic valve
31
. The 
echocardiography findings of PHT are summarized in the figure. Based upon 
a Doppler echocardiography study, it can be determined if PHT is grouped 
as - likely, unlikely, or possible
16
:  
PHT is likely if the PASP is >50, the TRV is >3.4  
PHT is unlikely if the PASP is ≤36, the TRV is ≤2.8, and there are no 
other suggestive findings,  
PHT is possible with other combinations of findings. One of the 
limitations of Doppler echocardiography is that it may be misleading in the 
assessment of patients with suspected pulmonary hypertension, especially 
when an inadequate tricuspid regugatation   jet is over-interpreted. This was 
explained by an observational study of 65 patients with various types of 
PH
32
. The pulmonary arterial pressure estimated by Doppler 
echocardiography was ± 10 mmHg   than what was obtained by right heart 
catheterization in 48 percent of patients. 
Overestimation and underestimation of pulmonary arterial pressure 
occurred with similar frequency, although the magnitude of the 
underestimation was greater. A major limitation of the study was that 
catheterization and Doppler echocardiography were not performed 
simultaneously.  
The study supports our opinion that there should be a low threshold to 
evaluate patients with suspected pulmonary hypertension via right heart via 
right heart catheterization. Despite its limitations, Doppler echocardiography 
detects PHT with greater accuracy than clinical history and physical 
examination. 
Study place: 
 Conducted with IP/OP clinic of dept of Nephrology in PSG IMS&R 
Coimbatore.  
Study population: 
Patient diagnosed with CKD on MHD who has  pre transplant workup 
and renal transplant  in hospital done during time period of 3 years will be  
included in the study ,based on the inclusion and exclusion criteria . Total 
number of patients  were 75 out of which 55 was included in the study after 
the application of criteria & after obtaining written informed consent  . 
Study period: 
The study was conducted during the time period of July 2011 – 
December 2013.  
 Inclusion criteria:  
1. CKD on MHD, who have undergone renal transplantation  
2. Mild and moderate Pulmonary hypertension  
3. CKD due to all etiologies and patient of all age group were selected. 
4. Individuals who obtained consent to participate in the study. 
Exclusion Criteria:  
1. Not fit for renal transplantation.  
2. Sever pulmonary hypertension 
3. COPD 
4. Parenchymal lung disease 
5. Chest wall disease 
6. Previous h/o PH 
7. Pulmonary embolism 
8. Smoker >10 yr duration 
9. Collagen vascular Disease  
10. Valvular heart disease 
 Study design:  
Cross sectional/ sample – convenience sampling.  
Data collection: 
 Using Questionnaires, chart review for lab values and 
echocardiography.  
Statistical analysis:  
1. Descriptive statistic for prevalence of PH undergone renal 
transplantation. 
2. Inferential statistics using non parametric tests for qualitative and                          
‘t’ Test for Quantitative variables will be carried out.     
                                           
 
 
PROTOCOL 
Initial assessment 
Patient Clinical history, Family history, Blood group, Duration of illness and 
RRT 
 
Pre transplant work up 
Laboratory parameters, Doppler echocardiography USG abdomen, Renal CT 
Angiography, DTPA DMSA scan, General assessment (Cardiology, ENT, 
Ophthalmology, O&G) & fitness  
 
Renal transplantation 
 
Follow Up 
Regular Monthly follow up. 
3 & 6 months Echocardiography 
 
 OBSERVATION AND RESULTS 
 
TABLE.1. INCIDENCE OF PULMONARY HYPERTENSION 
 
Pre- transplant No of patients Percentage (%) 
No 
33 60.0 
Yes 
22 40.0 
Total 55 100.0 
 
 
 
 
 
 
 
 
 TABLE 2. AGE RATIO 
 
Age No. of patients Percentage (%) 
<20 2 3.6 
21-30 8 14.5 
31-40 26 47.3 
41-50 12 21.8 
51-60 5 9.1 
61-70 2 3.6 
Total 55 100.0 
 
 
 
 
 
 
 
 
 TABLE 3. AGE AND PRE-TRANSPLANT 
Age  Pre-transplant P value 
 No Yes Total 
<20 No. 1 1 2  
 
 
 
 
 
0.017 
 % 50.0% 50.0% 100.0% 
21-30 No. 8 0 8 
 % 100.0% 0% 100.0% 
31-40 No. 18 8 26 
 % 69.2% 30.8% 100.0% 
41-50 No. 4 8 12 
 % 33.3% 66.7% 100.0% 
51-60 No. 2 3 5 
 % 40.0% 60.0% 100.0% 
61-70 No. 0 2 2 
 % 0% 100.0% 100.0% 
Total No. 33 22 55 
 % 60.0% 40.0% 100.0% 
 
 
 TABLE 4. SEX RATIO AND INCIDENCE 
 
Gender No. of patients Percentage (%) 
Male 34 61.8 
Female 21 38.2 
Total 55 100.0 
 
 
 
 
 
 
 
 
 
 
 TABLE 5. GENDER AND PRE-TRANSPLANT 
 
Gender  Pre-transplant P value 
  No Yes Total 
Male No. 20 14 34  
 
 
0.524 
 
 
 
 
 
 % 58.8% 41.2% 100.0% 
Female No. 13 8 21 
 % 61.9% 38.1% 100.0% 
Total No. 33 22 55 
 % 60.0% 40.0% 100.0% 
 
 
 
 
 
 
 
 
  
TABLE .6. GENDER RELATION WITH PH 
 
 
Gender No of patients Percentage (%) 
Male 
7 50.0 
Female 
7 50.0 
Total 
14 100.0 
 
 
 
 TABLE.7. RELATIONSHIP OF DONOR 
 
Relationship of donor No. of patients Percentage (%) 
Related 42 76.4 
Unrelated 12 21.8 
Cadaver 1 1.8 
Total 55 100.0 
 
 
 
 
 
 
 
 
 
 
 TABLE 8. HYPERTENSION 
 
Hypertension No. of patients Percentage (%) 
No 34 61.8 
Yes 21 38.2 
Total 55 100.0 
 
 
 
 
 
 TABLE. 9. HYPERTENSION WITH AGE 
 
Age  SHT  P value 
 No Yes Total 
<20 No. 1 1 2  
 
 
 
 
 
 
 
 
0.053 
 % 50.0% 50.0% 100.0% 
21-30 No. 8 0 8 
 % 100.0% 0% 100.0% 
31-40 No. 18 8 26 
 % 69.2% 30.8% 100.0% 
41-50 No. 4 8 12 
 % 33.3% 66.7% 100.0% 
51-60 No. 2 3 5 
 % 40.0% 60.0% 100.0% 
61-70 No. 1 1 2 
 % 50.0% 50.0% 100.0% 
Total No. 34 21 55 
 % 61.8% 38.2% 100.0% 
 
 
 
 TABLE.10. HYPERTENSION ESRD WITH PH: 
SHT No of patients Percentage (%) 
No 8 57.1 
Yes 5 42.9 
Total 13 100.0 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 TABLE 11: SHT & PRE TRANSPLANT PH: 
 
 
  Mild Moderate Total P value 
No No 
4 4 8 
 
 
 
0.471 
 % 
50.0% 50.0% 100.0% 
Yes No 
2 3 5 
 % 
33.3% 66.7% 100.0% 
Total No 
6 8 14 
 % 
42.9% 57.1% 100.0% 
 
 
 
 
 
 
 
 
 
 TABLE.12. DIABETES & ESRD IN RELATION WITH AGE PRE 
TRANSPLANT GROUP 
 
Age  DM P value 
 No Yes Total 
<20 No. 2 0 2  
 
 
 
 
 
0.001 
 % 100.0% 0% 100.0% 
21-30 No. 8 0 8 
 % 100.0% 0% 100.0% 
31-40 No. 26 0 26 
 % 100.0% 0% 100.0% 
41-50 No. 7 4 11 
 % 63.6% 36.4% 100.0% 
51-60 No. 2 3 5 
 % 40.0% 60.0% 100.0% 
61-70 No. 1 1 2 
 % 50.0% 50.0% 100.0% 
Total No. 46 8 54 
 % 85.2% 14.8% 100.0% 
 
 
 
 
  
TABLE .13. DIABETIC ESRD WITH PULMONARY 
HYPERTENSION: 
 
 
DM with ESRD No of patients Percentage (%) 
No 9 64.3 
Yes 4 35.7 
Total 14 100.0 
 
 
 
 
 
 
 
 
 
 
 
 
  
TABLEBLE.14. DM & PRE TRANSPLANT 
 
 
  Mild Moderate Total P value 
No No 4 5 9  
 
0.657 
 % 44.4% 55.6% 100.0% 
Yes No 2 2 4 
 % 40.0% 60.0% 100.0% 
Total No 6 7 13 
 % 42.9% 57.1% 100.0% 
 
 
 
 
 
 
 
 
 
 
 
 TABLE 15. CORONARY ARTERY DISESAE IN TRANSPLANT 
POPULATION 
 
CAD 
 
No of patients Percentage (%) 
No 43 78.2 
Yes 12 21.8 
Total 55 100.0 
 
 
 
 
 
 
 
 
 TABLE.16. ESRD WITH CORONARY ARTERY DISEASE AND PH: 
 
 
CAD No of patients Percentage (%) 
No 11 84.7 
Yes 2 15.3 
Total 13 100.0 
 
 
 
 
                     
 
 
 
 
 
 
 TABLE.17. CAD & PRE TRANSPLANT: 
 
 
  Mild Moderate Total P value 
No No 6 5 11  
 
0.154 
 % 54.5% 45.5% 100.0% 
Yes No 0 2 2 
 % .0% 100.0% 100.0% 
Total  6 7 13 
  42.9% 57.1% 100.0% 
 
 
 
 
 TABLE. 18. PATIENTS WITH MULTIPLE RISK FACTORS AND 
PH: 
 
 
Pt. with DM, 
SHT,CAD 
No of patients Percentage (%) 
No 
11 78.6 
Yes 
3 21.4 
Total 14 100.0 
 
 
 
 
 
 TABLE.19.PATIENT WITH MULTIPLE RISK FACTORS & PRE 
TRANSPLANT: 
 
 
  Mild Moderate Total P value 
No No 6 5 11  
 
0.154 
 % 54.5% 45.5% 100.0% 
Yes No 0 3 3 
 % .0% 100.0% 100.0% 
Total No 6 8 14 
 % 42.9% 57.1% 100.0% 
 
 
 
 
 
 
 
 
TABLE .20.  POST TRANSPLANT AFTER 3&6 MONTHS 
 
 
  Normal Mild Total P value 
No No 11 0 11  
 
0.003 
 % 100.0% .0% 100.0% 
Yes No 0 3 3 
 % .0% 100.0% 100.0% 
Total No 11 3 14 
 % 78.6% 21.4% 100.0% 
 
 
 
 
 TABLE .21.OUTCOME OF PH IN POST TRANSPLANT 3 MONTHS: 
 
 
Post transplant after 3 
months 
No of patients Percentage (%) 
Normal 
11 78.6 
Mild 
3 21.4 
Total 
14 100.0 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
TABLE .22. OUTCOME OF PH IN POST TRANSPLANT 6 MONTHS: 
   
Post transplant after 6 
months 
No of patients Percentage (%) 
Normal 11 78.6 
Mild 3 21.4 
Total 
14 100.0 
 
 
 
 
 
 
DISCUSSION 
 It’s well known fact that in CKD G5D cardiovascular disease is most 
common cause of mortality which is mostly manifested as LV dysfunction, 
Ischemic heart disease, or acute Myocardial infarction. The other forms of 
the cardiovascular disease, other rare manifestations may be pulmonary 
hypertension
37
. But only limited data is available on pulmonary hypertension 
in ESRD and Post transplant outcome. 
 We examined 75 patients out of which 55 cases underwent Renal 
Transplant in our institute & also fulfilled the inclusion criteria was taken up 
for the study, 41 patients were excluded by clinical history and examination, 
laboratory investigation and exclusion criteria 
(5,7,15,21)
. Doppler 
echocardiography was done in all 55 patients as a part of pre transplant work 
up and in patient with PH post operatively 3 months and 6 months 
echocardiography was done. Since it’s a non invasive parameter for 
assessing pulmonary hypertension in this population during monthly OPD 
follow up.  
 Among the 55 patients who undergone renal transplantation 22 
patients were found to have pulmonary hypertension in the population 
(40%). 
 The Distribution age group  and sex of the study population
13
 was 
total of 55 patients out of which 31males(41.2%) and 21 females38.1%, and 
only 2 were of 20 years, 26 were of 31-40 years, 12patients were 41-50 
years, 5 patients were 51-60, and pre transplant pulmonary hypertension ‘p’ 
value of 0.017. 
 We compared gender ratio and found that pulmonary hypertension 7 
male and 7 female, who fits in our inclusion criteria. As overall population 
male are more common with 41.2%.and female of 38.1% with ‘p’ value of 
0.524. in pulmonary hypertension group the ration is 1:1. 
 Most of our cases are live related donor with 76.2% unrelated are 
21.8%, and deceased donor of only 1 patient. 
  We analysed systemic hypertension in our all population who 
underwent renal transplant showed about 38.2%, with age related most 
common is 3
rd
 and 4
th
 decade of life with 30.6% and 66.6% and ‘p’ value of 
0.053. 
 Out of 14 patients (42.9%) Hypertension ESRD, of which 2 had mild 
pulmonary hypertension, 3 had moderate PH with ‘p’ value of 0.471. 
 Among the pre transplant group we found 8 cases (40%) having DM, 
when compared to age relation compared 36.4% aged from 41-50, and only 
3 were from 51-60. PH with ‘p’ value of 0.001. 
 In association with pulmonary hypertension and Diabetic ESRD we 
found only 4 patients, 2 patients with mild PH, 2 with moderate PH. 
calculating a ‘p’ value of 0.657. 
 In our study group we found 12cases to have coronary artery disease 
and ESRD 21.8%outof 55 patients, with pulmonary artery hypertension 2 
had moderate PH (45.4%) ‘ p’ value of 0.154. 
 We also analysed the data and found 3 patients (21.4%) had multiple 
risk factors like SHT, DM.CAD& ESRD in the study group of 14 patients 
(78.4%) ‘P’ value of 0.154.  
 In total of pre transplant workup with pulmonary Hypertension we 
had 14 patients with mild and moderate PH, 8 cases Severe PH were not 
included in this study due to exclusion criteria.   
 Out of 55 patients who received renal transplant 22 had pulmonary 
hypertension of which 14 patients were included for analysis. 
 Out of 14 patients 5had Hypertension and ESRD of which 2 had mild 
PH and 3 had moderate PH, 4 patients had diabetes and ESRD of which 2 
had mild PH, 2 had moderate PH, 2 patients had coronary artery disease and 
ESRD both had moderate PH. 
 3 patients had SHT, DM, CAD & ESRD. All 3 had moderate PH. 
 Mild and moderate PH in Hypertensive ESRD, Diabetic ESRD, 
Coronary artery disease & ESRD, became normal 3 and 6 month post 
transplant. 
 The moderate PH in the hypertension, Diabetic, Coronary artery 
disease & ESRD, group became mild PH in post Transplant 3and 6 months. 
 There was a significant favourable outcome in patients who  
underwent Renal Transplant when followed  up (with 
echocardiography)
(3,5,7)
 after first 3 months of transplant showed a ‘p’ value 
of 0.002. And follow up after 6moths duration showed a good prognosis 
improved to mild PH showed a ‘p’ value of 0.008. Serife savas et. al., 
concluded that patients have PH with ESRD has benefited by renal 
transplantation. 
 Till date only one study on pulmonary hypertension in post renal 
transplantation with Doppler echocardiography was done by Issa et al 
reported pulmonary hypertension in ESRD group of patient’s Doppler 
echocardiography was done as a part of workup.  David et al., showed that 
Non-invasive detection of pulmonary hypertension prior to renal 
transplantation is a predictor of increased risk for early graft dysfunction. 
 
 
 
 
 
 
 
 
 
 
LIMITATIONS 
 
 
 The major limitations of this study are small sample size.  
  Observational study  
 Echocardiography which has 
subjective variation, used as a parameter. 
 Cases of Severe Pulmonary hypertension are excluded because they 
are not fit for renal transplant. 
 Right sided cardiac catheterization and Doppler echocardiography 
were not performed simultaneously. 
 
 
 
 
 
 
 
 
 
 
SUMMARY AND CONCLUSION 
 
 14 patients with pulmonary hypertension and ESRD who has 
undergone renal transplant were followed up in the post transplant 
period. PH became normal in 11 patients during 3
rd
 and 6
th
 month. Of 
these 11 patients 5 had Hypertension and ESRD, 4 had Diabetic and 
ESRD, 2 had Coronary artery disease and ESRD. 
 In the remaining 3 patients moderate PH in the pre transplant period 
regressed to mild PH on follow up. All the 3 co-morbid factors (DM, 
SHT, CAD), were present in this sub- group which may be the reason 
for incomplete resolution of PH. 
 Renal transplant offers a significant resolution of PH in all sub groups 
in post transplant period. 
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ANNEXURE-I 
LIST OF ABBREVIATIONS USED 
 
 
PAH :  Pulmonary  Arteial Hypertension 
PH :  Pulmonary Hypertension 
CKD           :  Chronic Kidney Disease 
CAD :  Coronary Artery Disease 
DM :  Diabetes Mellitus 
SHT :  Hypertension 
CVD :  Cardio Vascular Disease 
ECG :  Electro Cardiogram 
CHD :  Coronary Heart Disease 
COPD  :  Chronic Obstructive Pulmonary Disease 
HIV :  Human Immunodeficiency Virus 
WHO          :  World Health Organization 
NO :  Nitric Oxide 
ADMA      :  Asymmetric Dimethylarginine 
 
ANNEXURE-II 
CASE PROFORMA 
 
Name:                       Age:                 Sex: 
IP No:                                        OP No:  
Diagnosis:  Native Kidney Disease: 
Causes of renal failure: 
Duration of temp catheter: 
Duration of AVF: 
Risk Factors:  DM / SHT / Smoker / Family History 
General examination: 
BP: 
PR: 
SPO2: 
HR: 
CVS: 
RS: 
P /A: 
CNS:  
Pre transplant work up & Echocardiography  
Renal transplant date:  
Pre transplant out come:  
Echocardiography in first 3 months: 
Echocardiography in first 6 months: 
 

 
